Metformin restores marrow mesenchymal lineage homeostasis in glucocorticoid-induced osteoporosis through a gut microbiota–butyrate–ERK1/2 axis

The human skeleton is not merely a static frame of bone; it is a living tissue that constantly rebuilds itself, a process managed by a specialized group of cells in the bone marrow. These cells act as a crossroads, capable of turning into either bone-forming builders or fat-storing cells. Under normal conditions, this balance ensures strong, healthy bones. However, when the body is exposed to high levels of corticosteroids—powerful medicines often used to calm severe inflammation and immune reactions—this delicate equilibrium can shatter. The medicine, while saving lives in other ways, can force these marrow cells to abandon their role as bone builders and instead become fat cells. This shift leads to a dangerous condition where bones become weak and brittle, a problem known as glucocorticoid-induced osteoporosis. For decades, doctors have known that these drugs cause bone loss, but the precise moment when the damage begins and the hidden mechanisms driving it have remained somewhat obscure, particularly in young people whose skeletons are still growing.

A team of researchers at Nanjing Agricultural University has now peeled back the layers of this mystery, revealing that the damage starts much earlier than previously thought and that the solution may lie not just in the bone, but in the gut. By studying mice that were given high doses of a corticosteroid similar to those used in human medicine, the scientists discovered that the accumulation of fat within the bone marrow is actually one of the very first signs of trouble, appearing weeks before the bone structure itself begins to visibly crumble. This early shift suggests that the body's internal environment is changing long before the skeleton shows obvious signs of weakness. The researchers then tested whether metformin, a common medication used to treat diabetes, could stop this process. They found that it could, but not by acting directly on the bone. Instead, the drug worked by reshaping the community of bacteria living in the intestine, which in turn produced a specific chemical signal that traveled to the bone marrow and convinced the stem cells to stop making fat and start making bone again.

The study began by tracking the timeline of injury in young mice over several weeks. The researchers observed that after just two weeks of steroid exposure, the bone marrow was already filling up with fat cells, even though the bone structure itself still looked intact. By the fourth week, the bone had begun to deteriorate significantly, losing its density and strength. This confirmed that the conversion of marrow cells into fat was an early warning sign, occurring before the skeleton collapsed. When the researchers added metformin to the treatment regimen, the mice were protected. Their bones remained dense and strong, and the dangerous buildup of fat in the marrow was prevented. The drug did not simply lower blood sugar; it actively restored the ability of the marrow stem cells to choose the right path, favoring bone formation over fat storage.

To understand how a drug taken by mouth could protect the bones, the team turned their attention to the gut. They analyzed the bacteria living in the intestines of the mice and found that the steroid treatment had disrupted the natural balance of the microbial community. The metformin treatment, however, rewired this ecosystem. It encouraged the growth of specific beneficial bacteria while suppressing harmful ones. Crucially, this reshaped community produced higher levels of a substance called butyrate, a short-chain fatty acid that serves as a fuel source for the gut lining and a signaling molecule for the body. The researchers found that the mice receiving metformin had restored levels of butyrate in their intestines, and this chemical was linked to the recovery of the intestinal barrier, which had been weakened by the steroids.

The most compelling evidence that the gut was the key to the bone's protection came from a series of experiments where the researchers swapped the gut bacteria between mice. They took fecal matter from mice that had been treated with both steroids and metformin and transplanted it into other mice that had been cleared of their own gut bacteria. Remarkably, the recipient mice, which had never received the drug themselves, developed stronger bones and healthier marrow. They avoided the fat accumulation and bone loss seen in mice that received bacteria from untreated, sick animals. This proved that the protective effect was carried by the bacteria themselves, not just by the drug. The bacteria from the treated mice had learned to produce the right signals to keep the bones safe.

Further investigation revealed exactly how this signal worked. The researchers identified butyrate as the primary messenger. When they added pure butyrate to bone marrow cells in a dish, it reversed the harmful effects of the steroids, pushing the cells back toward becoming bone rather than fat. However, this process required a specific switch inside the cells to be flipped. The team discovered that butyrate activated a signaling pathway known as ERK1/2, which acts like a molecular on-switch for bone formation. When they blocked this switch with a specific inhibitor, the benefits of butyrate disappeared, and the cells reverted to their fat-making state. This confirmed a clear chain of events: the drug changed the gut bacteria, the bacteria produced butyrate, and the butyrate activated a specific pathway in the bone cells that restored their ability to build bone.

The findings offer a new perspective on how to protect the skeleton during necessary medical treatments. While corticosteroids are essential for managing many serious conditions, their side effects on the skeleton have long been a major concern, especially for young people whose bones are still developing. This research suggests that the gut microbiome plays a central role in this process, acting as a bridge between the digestive system and the skeleton. By restoring the balance of gut bacteria, it may be possible to shield the bones from damage without compromising the therapeutic benefits of the steroids. The study does not claim that metformin is a cure-all or that it should replace existing treatments, but it does provide a clear mechanistic explanation for how the gut and bone communicate. It highlights that the health of the skeleton is deeply intertwined with the health of the gut, and that targeting this connection could open new doors for preserving bone strength in the face of powerful medications.